Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation

View/ Open
El-Tanani_British_Journal_of_Haematology.pdf (1.325Mb)
Download
Publication date
2015Author
Maxwell, P.Melendez-Rodriguez, F.
Matchett, K.B.
Aragones, J.
Ben-Califa, N.
Jackel, H.
Hengst, L.
Lindner, H.
Bernardini, A.
Brockmeier, U.
Fandrey, J.
Grunert, F.
Oster, H.S.
Mittelman, M.
El-Tanani, Mohamed
Thiersch, M.
Schneider Gasser, E.M.
Gassmann, M.
Dangoor, D.
Cuthbert, R.J.
Irvine, A.
Jordan, A.
Lappin, T.R.
Thompson, J.
Neumann, D.
Keyword
Cancer anaemia; Recombinant erythropoietin; Erythropoietin receptor; Antibody; Risk assessmentRights
© 2014 Wiley This is the peer reviewed version of the following article: Maxwell P, Melendez-Rodriguez F, Matchett KB et al. (2015) Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation. British Journal of Haematology. 168: 429-442, which has been published in final form at http://dx.doi.org/10.1111/bjh.13133 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.Peer-Reviewed
Yes